Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Sponsor: Arovella Therapeutics Ltd
Summary
Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
Official title: A Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101, Allogeneic, Off-the-shelf, CD19-directed CAR-iNKT Cells in Patients With CD19+ Non-Hodgkin Lymphoma and Leukemia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2026-04-01
Completion Date
2030-08-30
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
ALA-101
Single IV infusion of ALA-101 post chemotherapy conditioning with Fludarabine and Cyclophosphamide
Locations (3)
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Epworth HealthCare
Richmond, Victoria, Australia